Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID-19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell

Emerging Therapies for the Management of Richter Transformation

A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma

Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies

Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance

How I manage mantle cell lymphoma: indolent versus aggressive disease

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Characteristics and Outcomes of Older Patients With Classical Hodgkin Lymphoma: An Australasian Lymphoma Alliance, and Lymphoma and Related Diseases Registry Study

Using next generation sequencing to guide treatment of co-existing T-cell lymphoma and chronic myelomonocytic leukemia